Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion
Cardiovascular Intervention and Therapeutics · 2026-07 · 41 (3) · 660-669
DOI: 10.1007/s12928-026-01255-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, online erschienen am 03.03.2026. Verfasst von Sho Nakao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan. shotwins0601@gmail.com. Hauptthemen laut MEDLINE: Popliteal Artery, Femoral Artery, Stents, Platelet Aggregation Inhibitors. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
In-stent occlusions (ISO) in femoropopliteal lesions increase the risk of repeat occlusion after revascularization for ISO and worsen limb prognosis. This study investigated the impact of dual-pathway inhibitor therapy (DPIT) on clinical outcomes after femoropopliteal ISO revascularization. We retrospectively analyzed 120 limbs in 113 symptomatic patients who underwent EVT for femoropopliteal ISO between August 2012 and October 2021. After ISO revascularization, antithrombotic therapy was switched to DPIT in 39 limbs, whereas dual antiplatelet therapy (DAPT) was continued in 81 limbs. The primary endpoint was repeat ISO. Safety endpoints were major bleeding defined as Bleeding Academic Research Consortium (BARC) grade 3 or 5 bleeding and International Society on Thrombosis and Haemostasis (ISTH) major bleeding. Cox proportional hazards models were used to identify prognostic factors. To adjust for baseline imbalances, inverse probability of treatment weighting (IPTW)-weighted Cox model were performed. One-year freedom from repeat ISO was higher with DPIT than with DAPT (74.7 ± 7.9% vs. 49.1 ± 6.3%; p = 0.029). One-year freedom from BARC 3/5 bleeding (97.4% vs. 97.3%; p = 0.99) and ISTH major bleeding (87.8% vs. 90.2%; p = 0.83) were similar between the two groups. In multivariable analysis, DPIT was associated with lower repeat ISO risk (hazard ratio [HR] 0.41; p = 0.027), whereas chronic limb-threatening ischemia (HR 2.42; p = 0.016) and poor below-the-knee runoff (HR 3.38; p = 0.014) increased risk. In the IPTW-weighted Cox model, DPIT remained associated with reduced repeat ISO (HR 0.39, 95% CI 0.16-0.97; p = 0.043). Switching to DPIT after femoropopliteal ISO revascularization significantly reduced the risk of repeated ISO without increasing major bleeding events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan. shotwins0601@gmail.com.
- Cardiovascular Division, Osaka Police Hospital, Osaka, Japan.
- Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
- Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabaso, Amagasaki, 660-8511, Hyogo, Japan.
Zitieren
APA
Nakao, S., Iida, O., Takahara, M., Okamoto, S., Ishihara, T., Tsujimura, T., Hata, Y., Higashino, N., & Mano, T. (2026). Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion. Cardiovascular Intervention and Therapeutics, 41(3), 660-669. https://doi.org/10.1007/s12928-026-01255-5
Vancouver
Nakao S, Iida O, Takahara M, Okamoto S, Ishihara T, Tsujimura T, et al. Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion. Cardiovascular Intervention and Therapeutics. 2026;41(3):660-669. doi:10.1007/s12928-026-01255-5
BibTeX
@article{Nakao2026,
author = {Nakao, Sho and Iida, Osamu and Takahara, Mitsuyoshi and Okamoto, Shin and Ishihara, Takayuki and Tsujimura, Takuya and Hata, Yosuke and Higashino, Naoko and Mano, Toshiaki},
title = {Impact of dual-pathway inhibitor therapy on outcomes after femoropopliteal in-stent occlusion},
journal = {Cardiovascular Intervention and Therapeutics},
year = {2026},
volume = {41},
number = {3},
pages = {660--669},
doi = {10.1007/s12928-026-01255-5}
}
EUVIMED